The news is directly about Marinus Pharma and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term upside potential of the stock. However, the impact on the stock price is uncertain as the 'Buy' rating might still attract investors.